Perioperative medicine

NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS

Retrieved on: 
Tuesday, April 2, 2024
Perioperative medicine, Database, Pain, Patient, Anesthesiology, City, News, Pain management, General surgery, Fever, Safety, NSAID

NASHVILLE, Tenn., April 2, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced the release of a Special Report evaluating the growing amount of current data supporting the use of its Caldolor® product (intravenous ibuprofen, or IVIB) as a standard of care for the treatment of pain and fever in adults, children and infants.

Key Points: 
  • As part of a comprehensive safety and efficacy developmental plan, IVIB was studied in various treatment areas, including surgical pain, fever and nonsurgical acute pain.
  • IVIB is the only non-opioid injectable analgesic approved for use in children as young as 3 months of age.
  • "Pain management has become one of the most common health care problems," said A.J.
  • "As this new report states, comprehensive multimodal pain regimens have become key in preventing pain and optimizing pain control, while minimizing the need for opioids.

New Study Evaluates the Use of Masimo PVi® As an Indicator of Fluid Responsiveness to Guide Goal-Directed Fluid Therapy in Elderly Patients Undergoing Gastrointestinal Surgery

Retrieved on: 
Monday, August 21, 2023
Research, Surgery, Medical Devices, Hospitals, Clinical Trials, Health Technology, Cardiology, Health, Science, Pulse, Infection, Therapy, Splenic infarction, Multimedia, CFT, PPV, Vomiting, PVI, MASI, Patient, SVV, Perioperative medicine, Ageing, Arrhythmia, Pulmonary edema, Fasting, Pneumonia, Medical imaging

stroke volume variation [SVV] and pulse pressure variation [PPV]), of being obtained via noninvasive Masimo rainbow SET® pulse oximetry and Pulse CO-Oximetry.

Key Points: 
  • stroke volume variation [SVV] and pulse pressure variation [PPV]), of being obtained via noninvasive Masimo rainbow SET® pulse oximetry and Pulse CO-Oximetry.
  • PVi is indicated as a noninvasive, dynamic indicator of fluid responsiveness in select populations of mechanically ventilated adult patients.
  • Patients were randomly assigned to the GDFT group (n = 107) or the conventional fluid therapy (CFT) group (n = 104).
  • In the GDFT group, fluid therapy was guided by PVi obtained from the photoplethysmographic waveform measured by fingertip rainbow® Pulse CO-Oximetry sensors.

Extracellular Vesicles & Cell-Free RNAs Conference 2023: Uniting Expertise - Dive into the World of Biological Investigations with Co-Located Sessions (Laguna Hills, CA - November 28-30, 2023) - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 25, 2023
Health, Biotechnology, University, Asia Pacific Advanced Network, Exhibition, Anesthesiology, Research, Oregon Health & Science University, University of Kansas, University of Washington, Beer, Personalized medicine, Therapy, Translational Genomics Research Institute, Biology, EVS, National Cancer Institute, Seminal vesicles, Assistant professor, National Football Foundation Distinguished American Award, Speaker, Perioperative medicine, Laboratory, NIH, Conference, Wine, Vaccine, Management, Pathology, Chemistry

The "Extracellular Vesicles & Cell-Free RNAs 2023" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Extracellular Vesicles & Cell-Free RNAs 2023" conference has been added to ResearchAndMarkets.com's offering.
  • Welcome to the Extracellular Vesicles & Cell-Free RNAs: Technologies Driving Biological Investigations 2023 Conference to be held in-person on-site in beautiful Laguna Hills, California.
  • There is an Extensive International Perspective at this Conference with Speakers, Poster Presenters, Sponsors, and Exhibitors from the US, Europe, and Asia/Pacific.
  • There is an extensive exhibit hall featuring companies from these fields enabling business development, partnering and networking.

Extracellular Vesicles & Cell-Free RNAs Conference 2023: Advancing Biological Research - Latest Innovations in EV/Exosomes Explored (Laguna Hills, CA - November 28-30, 2023)

Retrieved on: 
Monday, July 24, 2023
University, Asia Pacific Advanced Network, Exhibition, Anesthesiology, Research, Oregon Health & Science University, University of Kansas, University of Washington, Beer, Personalized medicine, Therapy, Translational Genomics Research Institute, Biology, EVS, National Cancer Institute, Seminal vesicles, Assistant professor, National Football Foundation Distinguished American Award, Speaker, Perioperative medicine, Laboratory, NIH, Conference, Wine, Vaccine, Management, Pathology, Chemistry

DUBLIN, July 24, 2023 /PRNewswire/ -- The "Extracellular Vesicles & Cell-Free RNAs 2023" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 24, 2023 /PRNewswire/ -- The "Extracellular Vesicles & Cell-Free RNAs 2023" conference has been added to ResearchAndMarkets.com's offering.
  • Welcome to the Extracellular Vesicles & Cell-Free RNAs: Technologies Driving Biological Investigations 2023 Conference to be held in-person on-site in beautiful Laguna Hills, California.
  • Bringing together researchers and industry participants from both academia and industry, this established event, will discuss the latest innovations and developments in EV/Exosomes fields from a Technology Development and Utilization Perspective.
  • There is an Extensive International Perspective at this Conference with Speakers, Poster Presenters, Sponsors, and Exhibitors from the US, Europe, and Asia/Pacific.

Hospital La Fe Expands Telehealth Program with Masimo W1™ for Preoperative Patients

Retrieved on: 
Thursday, June 22, 2023
Technology, Medical Devices, Surgery, Hospitals, Other Technology, Health Technology, Software, Hardware, General Health, Health, Anesthesiology, Multimedia, Doctor of Philosophy, Hospital, MASI, MD, Patient, Patient safety, Perioperative medicine, Heart rate, FDA, Nursing, Masimo

Masimo (NASDAQ: MASI) today announced that Hospital La Fe in Valencia, Spain, is expanding its telehealth and telemonitoring program with the Masimo W1™ advanced health tracking watch.

Key Points: 
  • Masimo (NASDAQ: MASI) today announced that Hospital La Fe in Valencia, Spain, is expanding its telehealth and telemonitoring program with the Masimo W1™ advanced health tracking watch.
  • Masimo W1, which offers accurate, continuous measurements of key physiological parameters, is available outside the U.S. as a medical device that integrates with the Masimo SafetyNet® remote patient management and telehealth platform.
  • Hospital La Fe, one of the highest ranked hospitals in Spain and the world, has been using Masimo SafetyNet with Radius PPG® tetherless monitoring as part of its enhanced recovery pathway program for post-surgical patients since last year.
  • View the full release here: https://www.businesswire.com/news/home/20230621541795/en/
    Masimo W1™ and Hospital La Fe, Valencia, Spain (Photo: Business Wire)
    Joe Kiani , Founder and CEO of Masimo, said, “Hospital La Fe has long set the bar for successful use of telehealth and virtual care – long before the pandemic.

Masimo Announces FDA 510(k) Clearance of Radius VSM™

Retrieved on: 
Monday, June 5, 2023
Public Relations, Investor Relations, General Health, Health, FDA, Medical Devices, Communications, Hospitals, Health Technology, Blood pressure, Cleveland Clinic, Pulse, Freedom, Anesthesiology, Respiratory rate, AVL, University Hospitals Cleveland Medical Center, Radius, Health technology, ECG, Multimedia, Temperature, Orientation, Doctor of Philosophy, Movement, II, FGS, Acoustic, Cardiac electrophysiology, Hospital, MASI, Oxygen saturation (medicine), MD, Patient, Nursing, Risk, Protocol, Electrocardiography, Perioperative medicine, Heart rate, Peter Hancock (professor), III, Halo, Telemetry, Safety, Medical device, Medical imaging, AVR

Masimo (NASDAQ: MASI) today announced that Radius VSM™ , a patient-worn, continuous multi-parameter vital signs monitor, has received FDA 510(k) clearance.

Key Points: 
  • Masimo (NASDAQ: MASI) today announced that Radius VSM™ , a patient-worn, continuous multi-parameter vital signs monitor, has received FDA 510(k) clearance.
  • Designed on a modular platform, Radius VSM allows clinicians to monitor a wide variety of physiological measurements, including Masimo SET® pulse oximetry , noninvasive blood pressure, temperature, respiration rate, and electrocardiography (ECG).
  • By combining the reliability and accuracy of larger bedside monitors with the comfort and freedom of a wearable device, Radius VSM allows ambulation and movement while ensuring patients remain continuously monitored.
  • From a technical perspective, we had no doubt about the reliability of the solution as we have been working with Masimo for many years now.

Baudax Bio Reports First Quarter Financial Results and Provides Business Update

Retrieved on: 
Friday, May 12, 2023
Transfer, Purchasing, IV, Anesthesiology, New Drug Application, Plasma protein binding, DRS, See, Associate, Development, Agent, Patient, National Association, Three Months, PSA, Amendment, Wilmington Trust, Credit agreements in South Africa, EMG, Pharmacokinetics, ATLA, Teenage Mutant Ninja Turtles (2003 TV series, season 6), IND, The Transfer Agreement, Safety, Volunteering, Bromide, NMB, University, Clinical research, Research, Good, National Railway Company of Belgium, Reversal, Series, Intubation, Perioperative medicine, Pharmaceutical industry, Vaccine, Birth control, Security (finance), Cryptocurrency, Asset, Anesthesia, Credit, Alkermes, Creditor

MALVERN, Pa., May 12, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today reported financial results for the quarter ended March 31, 2023, and provided a business update.

Key Points: 
  • MALVERN, Pa., May 12, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today reported financial results for the quarter ended March 31, 2023, and provided a business update.
  • Baudax Bio expects to complete nonclinical studies and manufacturing data required to support the IND for BX3000 in late summer of 2023.
  • Financial Results for the Three Months Ended March 31, 2023
    As of March 31, 2023, Baudax Bio had cash and cash equivalents of $3.8 million.
  • Baudax Bio reported net loss from continuing operations of $(7.4) million, or $(3.19) per share, for the three months ended March 31, 2023.

Envision Healthcare’s 2022 Clinical Impact Report Illustrates the Many Ways Teams Cared for and Positively Impacted Millions of People

Retrieved on: 
Thursday, April 27, 2023
Radiology, Managed Care, Surgery, Oncology, General Health, Health, Hospitals, Other Health, The Prince of Wales's Charitable Fund, Medicaid, Education, White stork, Centers for Medicare & Medicaid Services, Hurricane Ian, Research, Envision Healthcare, Equity, Colorectal Cancer Alliance, Hygiene, Medicare, Dominican Republic, Publication, Patient, Physician, Colorectal cancer, Inclusion, Perioperative medicine, Research institute, ET3, United Way, Organic, H. Lee Moffitt Cancer Center & Research Institute, Pharmaceutical industry, Nursing, Envision

In 2022, Envision clinicians continued outperforming national quality benchmarks while treating complex medical conditions and authoring two Centers for Medicare & Medicaid Services-approved national clinical quality measures.

Key Points: 
  • In 2022, Envision clinicians continued outperforming national quality benchmarks while treating complex medical conditions and authoring two Centers for Medicare & Medicaid Services-approved national clinical quality measures.
  • Through programs like Emergency Triage, Treat and Transport (ET3), Envision teams provided patients the right care at the right time and in the right place.
  • In 2022, Envision redefined its organizational structure to build a transformative care experience for patients and drive clinical innovation.
  • As part of their passion for improving healthcare worldwide, Envision clinicians and clinical support teammates cared for communities in need through Envision’s Global Health Initiative.

Baudax Bio Announces Positive Top-Line Final Results From Phase 2 Randomized Clinical Trial of BX1000

Retrieved on: 
Tuesday, April 25, 2023
Good, Bromide, Arm, Anesthesiology, National Railway Company of Belgium, Plasma protein binding, Clinical trial, NMB, Associate, Patient, University, Clinical research, Intubation, Perioperative medicine, Safety, New Drug Application, Pharmaceutical industry, Anesthesia

MALVERN, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today announced positive top-line results from its Phase 2 clinical trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery. Results of the study showed that BX1000 met the primary endpoint of readiness for intubation (evaluated as “Good” or “Excellent”) at all dose levels assessed. No severe adverse events were observed in any dose regimen.

Key Points: 
  • MALVERN, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today announced positive top-line results from its Phase 2 clinical trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery.
  • Results of the study showed that BX1000 met the primary endpoint of readiness for intubation (evaluated as “Good” or “Excellent”) at all dose levels assessed.
  • The BX1000 Phase 2 surgery trial is a randomized, double-blind, active-controlled clinical trial comparing three different doses of BX1000 to a standard dose of 0.6mg/kg rocuronium in a planned clinical trial of 80 adult patients undergoing elective surgery utilizing total intravenous anesthesia.
  • Additionally, the clinical trial evaluated the safety and tolerability profile of BX1000 and rocuronium in this patient population.

Baudax Bio to Host Key Opinion Leader Webinar to Discuss Results of Phase 2 BX1000 Trial

Retrieved on: 
Monday, April 24, 2023
Faculty, Bromide, University, American Board of Anesthesiology, Plasma protein binding, Uniformed Services University of the Health Sciences, Clinical trial, NMB, Associate, American Board of Commissioners for Foreign Missions, Memorial Hermann–Texas Medical Center, MD, Wilford Hall Ambulatory Surgical Center, Patient, Clinical research, Internal medicine, Fellow, Pain management, Outline of health sciences, Texas Medical Center, Air force, Perioperative medicine, Hospital, Principal, University of the Witwatersrand, FDA, Research, United States Department of the Air Force, Pharmaceutical industry, Dentistry, Anesthesiology, Analgesic, Anesthesia

The BX1000 Phase 2 surgery trial is a randomized, double-blind, active-controlled clinical trial comparing three different doses of BX1000 to a standard dose of 0.6mg/kg rocuronium in a planned trial of 80 adult patients undergoing elective surgery utilizing total intravenous anesthesia.

Key Points: 
  • The BX1000 Phase 2 surgery trial is a randomized, double-blind, active-controlled clinical trial comparing three different doses of BX1000 to a standard dose of 0.6mg/kg rocuronium in a planned trial of 80 adult patients undergoing elective surgery utilizing total intravenous anesthesia.
  • A live question and answer session will follow the formal presentations.
  • Todd M Bertoch, MD, is a diplomate of the American Board of Anesthesiology.
  • After receiving his Fellowship in the Faculty of Anesthesiologists in South Africa, he relocated to the Texas Medical Center in Houston.